This feasibility trial will test the use of photo-biomodulation (PBM) therapy, predominantly self-delivered in the patient's home for 12-weeks, following completion of radiotherapy treatment for head and neck cancer.

The primary objective is to establish feasibility of recruitment (uptake). Secondary objectives are to assess safety, additional elements of feasibility (adherence to the intervention, return of the device and attrition at the 3-month follow-up appointment) and acceptability of the trial to patients.

Secondary measures will be performed to assess trends in effects of the intervention (pre-post intervention, within-group measures) for managing lymphoedema and radiation fibrosis.

Inclusion Criteria:

1. Patient has provided written informed consent using the HOME-PBM patient information and consent form
2. Patient is referred to the Lymphoedema Clinic for the management of head and neck lymphoedema and/or radiation fibrosis
3. Previously received curative-intent treatment (surgery and/or [chemo]radiotherapy) for mucosal head and neck cancer
4. Patient is able to attend appointments in person
5. Adults aged 18 years or older at Screening
6. Patient able to speak and read English

Exclusion Criteria:

1. Patient has cognitive impairment that in the opinion of the Investigator would interfere with their ability to participate in the trial (e.g., complete outcome measures, perform the intervention)
2. Residual or recurrent disease within the head and neck
3. Has a diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc.)
4. Patient has tuberculosis or another form of virulent bacteria
5. Patient has a contraindication to receiving PBM treatment
6. Patient has no internet enabled device for telehealth video follow-up appointment